Myriad to Co-market Sividon Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics GmbH and Sividon Diagnostics today announced a deal granting Myriad the exclusive rights to co-market Sividon's EndoPredict prognostic test kit for breast cancer patients outside the US.

The deal leverages Myriad's 45-person international commercial team and will "significantly increase" the number of medical specialists and sales professionals supporting EndoPredict, according to the companies.

Myriad Genetics GmbH is the international subsidiary of Myriad Genetics and is based in Zurich.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.